论文部分内容阅读
目的观察参松养心胶囊联合美托洛尔对冠心病心律失常的治疗效果。方法 70例符合入选标准的患者随机按1∶1的比例分为参松养心胶囊联合美托洛尔组和美托洛尔组,治疗组口服参松养心胶囊1.6 g,每天3次;美托洛尔25 mg,口服,每天3次,4周为1个疗程。对照组单用美托洛尔25 mg,口服,每天3次,4周为1个疗程。结果治疗组治疗心律失常总有效率为88.6%,对照组为68.6%,差异有统计学意义(P<0.05);治疗组改善症状总有效率为91.4%,对照组为71.4%(P<0.05)。两组治疗4周后观察24 h动态心电图和临床症状的变化,疗效比较差异有统计学意义(P<0.05)。结论参松养心胶囊联用美托洛尔治疗冠心病室性早搏疗效比单用美托洛尔疗效明显增高,其疗效确切安全,无明显不良反应,值得临床推广。
Objective To observe the therapeutic effect of Shensong Yangxin Capsule combined with metoprolol on coronary heart disease. Methods Seventy patients who met the inclusion criteria were randomized into two groups according to the ratio of 1: 1: Shensongyangxin Capsule, metoprolol group and metoprolol group. The treatment group received Shengshenyangxin Capsule 1.6g three times per day. Tollor 25 mg, orally, 3 times a day, 4 weeks for a course of treatment. The control group received metoprolol 25 mg orally three times a day for 4 weeks as a course of treatment. Results The total effective rate of treatment of arrhythmia was 88.6% in treatment group and 68.6% in control group, the difference was statistically significant (P <0.05). The total effective rate of treatment group was 91.4% and that of control group was 71.4% (P <0.05) ). After 4 weeks of treatment, the changes of 24 h dynamic electrocardiogram and clinical symptoms were observed, the difference was statistically significant (P <0.05). Conclusion Shensongyangxin Capsule combined with metoprolol in the treatment of coronary heart disease premature ventricular contractions efficacy than metoprolol alone was significantly higher, its efficacy is safe, no obvious adverse reactions, is worth clinical promotion.